| |||
| |||
| |||
Clive Maund, CliveMaund.com(7/28/22) |
|||
|
|||
![]() |
André Uddin, Research Capital Corporation(7/28/22) |
||
|
|||
| |||
André Uddin, Research Capital Corporation(7/18/22) |
|||
|
|||
| |||
Clive Maund, CliveMaund.com(6/1/22) |
|||
|
|||
| |||
Clive Maund, CliveMaund.com(2/2/22) |
|||
|
|||
![]() |
André Uddin, Research Capital Corporation(1/28/22) |
||
|
Clive Maund – CliveMaund.com | |
![]() |
Bob Moriarty, Author – 321 Gold |
![]() |
Penny Queen, Mother, Investor and Social Media Leader |
![]() |
André Uddin – Research Capital Corporation |
8/3/2022 – Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference
7/28/2022 – Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
7/18/2022 – Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough
7/11/2022 – Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study
7/7/2022 – Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study
7/5/2022 – Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate
7/4/2022 – Algernon Pharmaceuticals Announces Closing of Public Offering of Units
6/27/2022 – Algernon Pharmaceuticals Announces Pricing of Public Offering of Units
6/22/2022 – Algernon Pharmaceuticals Announces Issuance of Patent for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis
6/21/2022 – Algernon Announces Patients Requested Ongoing Supply of Ifenprodil after IPF and Chronic Cough Phase 2 Study Ended
6/15/2022 – Algernon Pharmaceuticals Announces Public Offering of Units
6/13/2022 – Algernon Pharmaceuticals Announces Database Lock in Phase 2 Study of IPF and Chronic Cough
The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.See disclaimer for more details.
Advancing new drug treatments for billion dollar global disease markets. | |
Conducting multiple phase II clinical trials | |
Experienced management team & globally recognized medical advisory board |
![]() Q2 2021 |
U,S, FDA End-of-Phase 2 COVID-19 Study Meeting, Q2, 2021
|
![]() Q4 2021 |
Phase 2 trial for IPF and chronic cough data expected Q4, 2021.
|
![]() Q4 2021 |
Phase 1 Study planned for DMT, Q4 2021
|